ORCHPHARMA Orchid Pharma Q4 FY26 results (Jan–Mar 2026) and concall
Orchid Pharma reported a stable Q4 FY26 with revenue of INR238 crores and EBITDA of INR42.3 crores, indicating signs of recovery after a challenging FY26 marked by significant declines in full-year revenue and EBITDA. The company is advancing strategic initiatives, including the Dhanuka merger, which is poised to enhance EBITDA margins, and the 7ACA and Cefiderocol projects, with the latter's facility commissioning on schedule for late 2026. Despite delays in Enmetazobactam out-licensing and persistent market pressures, Orchid Pharma is prioritizing operational efficiency and the development o
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 55.1%, net profit up 15.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 263 | 194 −13% | 207 −5% | 368 +55% |
| EBITDA | 30 | 26 | 28 | -6 | -1 −105% | 2 −94% | 30 +8% |
| Net profit | 27 | 21 | 22 | -6 | -6 −121% | -13 −161% | 26 +16% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
